STOCK TITAN

Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the Morgan Stanley Global Healthcare Conference in New York on September 12, 2022. The management team will take part in a fireside chat at 12:30 p.m. Eastern Time. Interested individuals can access a live and archived webcast via the company’s Investors section on their website. Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating various diseases, particularly cancer and autoimmune disorders.

Positive
  • None.
Negative
  • None.

SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Monday, September 12th at 12:30 p.m. Eastern Time / 9:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Laura Cooper
205-908-5603
media@adaptivebiotech.com

 


FAQ

When is Adaptive Biotechnologies participating in the Morgan Stanley Global Healthcare Conference?

Adaptive Biotechnologies will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2022.

What time is the Adaptive Biotechnologies fireside chat at the conference?

The fireside chat is scheduled for 12:30 p.m. Eastern Time on September 12, 2022.

How can I access the webcast of Adaptive Biotechnologies' presentation?

You can access the live and archived webcast of the presentation on Adaptive Biotechnologies' website in the Investors section.

What is the focus of Adaptive Biotechnologies' research and products?

Adaptive Biotechnologies focuses on the genetics of the adaptive immune system to diagnose and treat diseases, including cancer and autoimmune disorders.

What stock symbol represents Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

ADPT Rankings

ADPT Latest News

ADPT Stock Data

785.29M
147.47M
1.93%
98.62%
6.43%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SEATTLE